CRISPR Therapeutics stock rebounds as Cathie Wood doubles down on gene-editing bets
Since the beginning of 2026, shares of CRISPR Therapeutics (CRSP) are down by about 11%. While that's not a great start to the year, there are plenty of reasons to be bullish. For one, Cathie Wood can&#apos;t get enough of CRSP stock, recently picking up another 438,000 shares across the ARK Innovation ETF (ARKK)ct-ratio:447/226;" src="https://our website-news-media-prod.aws.our website/EXCLSV/7e770d7be1e02369410295b6ed3be600/t650r0qb1xrrtojv.png" width="447" height="226"> and ARK Genomic Revolution ETF(ARKG)width="447" height="226">. On top of that, oversold shares are just starting to pivot from double-bottom support.ks/quotes/CRSP/technical-chart?plot=BAR&volume=total&data=DO&density=X&pricesOn=1&asPctChange=0&logscale=0&sym=CRSP&grid=1&height=500&studyheight=100">
